Their lead product candidate, Canvaxin, is a therapeutic cancer vaccine, and their other clinical stage antibodies include blinatumomab, MT110, adecatumumab, and MT293, which are being developed for the treatment of various cancers. They also have preclinical programs, such as MT203, which has potential applications in the treatment of inflammatory and autoimmune diseases, and are developing additional BiTE antibodies targeting different cancers. Micromet has also granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target.